Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £3.50 an issue!

July 2020 (Vol. 5 Issue 5)

Triptans for migraine

About the author: 

Triptans for migraine image

In the early 1990s, the drug companies released what seemed a miracle to any sufferer of migraines

In the early 1990s, the drug companies released what seemed a miracle to any sufferer of migraines. Sumatriptan (Imitrex(R) or Imigran(R)), a selective serotonin-receptor agonist, was said to abort a migraine attack before it took off in full flight.

This drug, and the other 'triptans', are molecular twins of serotonin (5-hydroxytryptamine, or 5-HT), a brain chemical that governs mood. As 5-HT is released during migraine attacks, it is likely to play a key role. But giving 5-HT can also bring on a migraine. Triptans block serotonin receptors, and the action is supposed to be selective, with no effects on the other 15 or so 5-HT receptors in the body (related to blood-clotting, the lungs, the gastrointestinal tract and many others).

Initially, sumatriptan had an astonishing profile, reducing headaches in 81-86 per cent of patients (N Engl J Med, 1991; 325: 316-21; JAMA, 1991; 265: 2831-5). Since then, the 'me-too drugs' industry has has been busy churning out quantities of sumatriptan act-a-likes - zolmitriptan, naratriptan (Amerge(R)), rizatriptan, almotriptan, frovatriptan and eletriptan - in the form of injections, tablets and even a nasal spray.

Drugs that cause . . . headaches
An embarrassing side-effect of this otherwise successful class of drugs is rebound headaches - when the medication becomes less and less effective until you get a headache when you go without it. More than a third of patients who initially found relief with sumatriptan suffered recurrent headaches, which the drug failed to reach (Eur Neurol, 1991; 31: 306-13). Some studies show that up to half the patients suffer rebound headaches.

Furthermore, many of the drug's side-effects suggest that the supposedly selective action is not so selective after all, affecting other 5-HT-receptor sites.

Other problems include chest pain similar to angina (in 5-8 per cent of patients), largely because the drug, as a vasoconstrictor, narrows blood vessels, thereby restricting blood flow and raising blood pressure. Consequently, the drug is out of bounds for anyone with a heart problem.

Although the later generation - eletriptan, naratriptan and rizatriptan - claims to have sorted out these adverse reactions, eletriptan still has all the side-effects of sumatriptan (Neurology, 2000; 54: 156-63), including flushing, palpitations, nasal discomfort, eye irritation, visual disturbances and agitation.

Heart attack and stroke
Individual case reports have been flowing in concerning patients with no known risk having either a heart attack or stroke within hours of taking a triptan. In Switzerland, one woman suffered a stroke within hours after injecting herself with two doses of sumatriptan; within 30 minutes of the second injection, her headache vastly increased, she began vomiting and experienced paralysis on the left side of her body before losing consciousness. In the US, when a woman's headache severely worsened, a later CT scan showed that she had suffered a cerebral haemorrhage (Neurology, 2001; 56: 1243-4). Other case reports describe fatal heart attacks with the drug among those with no history of cardiovascular disease (Lancet, 1993; 341: 861-2).

Nevertheless, a recent review of the data for migraine sufferers found no association between triptan use and stroke or heart attack (Neurology, 2004; 62: 563-8). Even though a cohort study (a simple comparison of data) doesn't count as a true scientific study like a prospective, randomised, double-blind trial, it will undoubtedly let the triptans off the hook for now.

Indeed, many researchers say that migraineurs naturally have a higher risk of stroke (Headache, 2003; 43: 90-5), although this is widely disputed (Headache, 2001; 41: 399-401). Also, triptans are contraindicated for patients with hemiplegic or basilar migraine because of possible cerebral vasoconstriction, indicating that doctors themselves believe there's a link (Neurol Clin, 2001; 19: 1-21).

If you must take a triptan . . .
Nicholas Bateman, of the Scottish Poisons Information Bureau, has compared all of the triptans and concluded that they are all much of a muchness. Although naratriptan seems to have fewer adverse reactions, there seems to be little to choose among them (Lancet, 2000; 355: 860-1). It also acts more slowly than the other triptans (see WDDTY vol 14 no 11 for alternatives for migraine).

What to do instead
Try acupuncture, which has recently proved to be highly effective for patients with chronic headache (BMJ, 2004; 328: 744-7).

Natural alternatives to statins image

Natural alternatives to statins

Insomnia image


You may also be interested in...

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.


Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2020 WDDTY Publishing Ltd.
All Rights Reserved